过去一年中添加的文章，按日期排序
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): A prospective, single-arm, phase II trial
Y Hu, J Chen, Y Shen, Y Wang… - Gynecologic …, 2024 - gynecologiconcology-online.net
3 天前 - … arm trial, eligible patients underwent 1 cycle of priming chemotherapy (cisplatin [75-80
mg/m 2 , IV] … disease (PD) received concurrent chemoradiotherapy (CCRT); patients who …
mg/m 2 , IV] … disease (PD) received concurrent chemoradiotherapy (CCRT); patients who …
[引用][C] Chemoradiotherapy response and the tumor microenvironment in a novel immunocompetent mouse model of cervical cancer
T McKinnish, N Muhammad… - Gynecologic …, 2024 - gynecologiconcology-online.net
3 天前 - … The in vitro responses of this cell line to cisplatin, … cell proliferation, Alamar blue
survival and clonogenic cell survival assays, flow cytometry for apoptotic fractions, and cell cycle …
survival and clonogenic cell survival assays, flow cytometry for apoptotic fractions, and cell cycle …
A prospective study on the application of para-aortic lymph node metastasis prediction model in locally advanced cervical cancer and its effect on prognosis (CQGOG …
D Zou, M Guo, M He, Q Li - Gynecologic Oncology, 2024 - gynecologiconcology-online.net
3 天前 - … /or pelvic lymph node dissection followed by concurrent chemoradiotherapy (CCRT)
(pelvic external beam radiotherapy [EBRT]/extended-field EBRT + cisplatin [40 mg/m 2 ] or …
(pelvic external beam radiotherapy [EBRT]/extended-field EBRT + cisplatin [40 mg/m 2 ] or …
[引用][C] Neoadjuvant tislelizumab plus chemotherapy among patients with locally advanced cervical cancer: A prospective, single-arm, phase II trial
J Sheng, W Liu, R Liu, C Liu… - Gynecologic …, 2024 - gynecologiconcology-online.net
3 天前 - … mg+ chemotherapy (paclitaxel 175 mg/m 2+ cisplatin 60 mg/m 2 or carboplatin
AUC 5) … progressive disease were transferred to concurrent chemoradiotherapy (CCRT). The …
AUC 5) … progressive disease were transferred to concurrent chemoradiotherapy (CCRT). The …
Alpelisib and Immunotherapy: A Promising Combination for Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
4 天前 - … 3-drug regimen (docetaxel 67.5 mg/m 2 on Day 1, cisplatin 67.5 mg/m 2 on Day 1,
and 5-… be followed by concurrent chemoradiotherapy (CRT) with 45 mg/m 2 weekly cisplatin. …
and 5-… be followed by concurrent chemoradiotherapy (CRT) with 45 mg/m 2 weekly cisplatin. …
Recognizing the Role for Conversion Therapy in Metastatic Esophageal Squamous Cell Cancer (ESCC): A Call for Future Study
AS Baskin, JB Velotta - Annals of Surgical Oncology, 2024 - Springer
4 天前 - … consists of surgery or chemoradiation therapy (CRT), … chemotherapy with DCF
or cisplatin and fluorouracil. These … chemoradiotherapy for patients with esophageal cancer: …
or cisplatin and fluorouracil. These … chemoradiotherapy for patients with esophageal cancer: …
Toripalimab combined with definitive chemoradiotherapy for locally advanced cervical squamous cell carcinoma patients (TRACE): A single-arm, phase I/II trial
D Ou, R Cai, WX Qi, C Cui, L Cao, SB Wang… - Cancer Immunology …, 2024 - Springer
8 天前 - … death ligand-1 (PD-L1) status, received toripalimab combined with concurrent
chemoradiotherapy (CCRT). CCRT included cisplatin (40 mg/m 2 , once weekly for 5 weeks), …
chemoradiotherapy (CCRT). CCRT included cisplatin (40 mg/m 2 , once weekly for 5 weeks), …
A case of salvage surgery following chemoradiotherapy and durvalumab for initially unresectable superior sulcus tumor with N3 involvement
T Manabe, M Kanayama, H Matsumiya… - General Thoracic and …, 2024 - Springer
11 天前 - … chemoradiotherapy (2 cycles of cisplatin plus vinorelbine with 60 Gy radiotherapy)
followed by durvalumab treatment for 1 year at a previous hospital. The PACIFIC regimen …
followed by durvalumab treatment for 1 year at a previous hospital. The PACIFIC regimen …
Transforming Lung Cancer Management: A Promising Case Study of Immune Checkpoint Inhibitor Success Following a Multidisciplinary Approach
T Nishimura, H Fujimoto, T Fujiwara, T Okano… - Diagnostics, 2024 - mdpi.com
14 天前 - … IIIb squamous cell carcinoma (cT2aN3M0) initially received chemoradiotherapy.
Two … Notably, she had undergone irradiation and cisplatin treatment just before the …
Two … Notably, she had undergone irradiation and cisplatin treatment just before the …
Efficacy and Safety of the Combination of Tislelizumab with Chemoradiotherapy in Oligorecurrence Esophageal Squamous Cell Carcinoma: A Prospective Phase II …
Z Zheng, XM Wang, X Liu, YD Zhao, N Yu… - International Journal of …, 2024 - redjournal.org
14 天前 - … This study aims to evaluate the feasibility and efficacy of neoadjuvant chemoradiotherapy
(NACRT) in patients with initially unresectable LACC. It is the largest single-center …
(NACRT) in patients with initially unresectable LACC. It is the largest single-center …